Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can surgery or radiation boost lung cancer control after targeted therapy?

NCT ID NCT07073365

Disease control Sponsor: Pusan National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded to a combination of osimertinib and chemotherapy. About 70 adults will receive local therapy and be followed to see how long the cancer stays under control. The goal is to improve outcomes without needing lifelong medication changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

\<Inclusion Criteria\> Participants must meet all of the following criteria to be eligible: 1. Age ≥ 20 years at the time of consent. 2. Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC). 3. Presence of activating EGFR mutation (exon 19 deletion or L858R). 4. Stage IV (metastatic) NSCLC at initial diagnosis. 5. Completion of four cycles of first-line osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). 6. Radiologic evidence of disease control (complete response, partial response, or stable disease) after systemic therapy. 7. Residual primary lung tumor suitable for local therapy (surgery or radiotherapy), as determined by multidisciplinary evaluation. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 9. Adequate organ function based on institutional laboratory criteria. 10. Ability to understand and willingness to provide written informed consent. \<Exclusion Criteria\> Participants will be excluded if they meet any of the following criteria: 1. Radiologic or clinical evidence of progressive disease during first-line osimertinib-chemotherapy. 2. Extensive, unresectable metastatic disease not amenable to local therapy. 3. Untreated or clinically unstable brain metastases. 4. Known contraindications to surgery or radiotherapy. 5. Active second malignancy requiring concurrent treatment. 6. Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results. 7. Pregnancy or breastfeeding at the time of enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epidermal growth factor receptor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epidermal growth factor receptor Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pusan National University Hospital

    RECRUITING

    Busan, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.